Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 06/12/19
End: 08/02/22
Due: 08/02/23
Phase: N/A
Priority: Normal
Start: 07/10/17
End: 11/16/20
Due: 11/16/21
Phase: N/A
Priority: Normal
Start: 05/31/15
End: 06/19/18
Due: 06/19/19
Phase: N/A
Priority: Normal
Start: 10/06/17
End: 02/21/23
Due: 02/21/24
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma | NCT04337931 | Apexigen America, Inc. | user2@example.com | None | 2019-06-12 | 2022-08-02 | 2023-08-02 | - | - | 2025-07-14 |
| CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab | NCT03123783 | Apexigen America, Inc. | user2@example.com | None | 2017-07-10 | 2020-11-16 | 2021-11-16 | - | - | 2025-07-14 |
| Study of the CD40 Agonistic Monoclonal Antibody APX005M | NCT02482168 | Apexigen America, Inc. | user2@example.com | None | 2015-05-31 | 2018-06-19 | 2019-06-19 | - | - | 2025-07-14 |
| APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers | NCT03165994 | Apexigen America, Inc. | user2@example.com | None | 2017-10-06 | 2023-02-21 | 2024-02-21 | - | - | 2025-07-14 |